Company Filing History:
Years Active: 2002-2003
Title: Rolf Ehrhardt: Innovator in Chronic Inflammatory Disease Models
Introduction
Rolf Ehrhardt is a notable inventor based in San Francisco, CA (US). He has made significant contributions to the field of biomedical research, particularly in the development of animal models for chronic inflammatory diseases. With a total of 2 patents, his work has paved the way for advancements in understanding and treating various inflammatory conditions.
Latest Patents
Ehrhardt's latest patents focus on innovative methods and compositions for creating and screening non-human animal models that exhibit chronic inflammation. One of his patents describes a method where immunocompromised host animals are injected with a population of immunocompetent effector cells, which are tolerant of the host's major histocompatibility antigens but reactive to specific antigens present in the host. This model is particularly useful for studying chronic inflammatory diseases such as psoriasis, rheumatoid arthritis, diabetes, inflammatory bowel disease, and multiple sclerosis. Another patent details the creation of an animal model for psoriasis, which mimics many histological characteristics of human psoriasis. This model allows for the investigation of chronic skin disorders and includes features such as rete pegs and severe acanthosis.
Career Highlights
Throughout his career, Rolf Ehrhardt has worked with prominent companies in the biotechnology sector, including Protein Design Labs, Inc. and Bioseek, Inc. His expertise in developing animal models has been instrumental in advancing research in chronic inflammatory diseases.
Collaborations
Ehrhardt has collaborated with notable colleagues, including Kenneth Hong and Cary L Queen. These partnerships have contributed to the success of his research and the development of innovative solutions in the field.
Conclusion
Rolf Ehrhardt's contributions to the development of animal models for chronic inflammatory diseases have significantly impacted biomedical research. His innovative approaches continue to enhance our understanding of these complex conditions and pave the way for future advancements in treatment.